Myriad Genetics to Release Third Quarter 2025 Financial Results on November 3, 2025

Rhea-AI Summary

Myriad Genetics (NASDAQ: MYGN) will release its third quarter 2025 financial results on November 3, 2025 after market close and will host an earnings conference call the same day at 4:30 PM ET. Management will provide a financial overview and business update for Q3 2025.

A live webcast will be available on Myriad’s Investor Relations website at investor.myriad.com. Telephone participants must register to receive a dial-in number and unique PIN. An archived webcast will be posted at investor.myriad.com following the call.

News Market Reaction – MYGN

+0.37%

1 alert

+0.37% Session close to close

$753.66M Market Cap

1.2x Rel. Volume

In the Oct 28 session, MYGN gained 0.37%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its third quarter 2025 earnings conference call at 4:30 pm ET on Monday, Nov. 3, 2025. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the third quarter 2025.

A live webcast of the conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. An archived webcast of the call will be available at investor.myriad.com following the call.

About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Investor Contact 
Matt Scalo 
(801) 584-3532 
IR@myriad.com 

Media Contact 
Kate Schraml
(224) 875-4493
PR@myriad.com

FAQ

When will Myriad Genetics (MYGN) release its Q3 2025 earnings and hold the conference call?

Myriad will release Q3 2025 results on November 3, 2025 after market close and hold the call at 4:30 PM ET the same day.

How can investors access the Myriad Genetics (MYGN) Q3 2025 earnings webcast?

The live webcast will be available at investor.myriad.com, with an archived replay posted there after the call.

Can I join the Myriad Genetics (MYGN) earnings call by phone and what is required?

Yes; telephone participation requires registration to receive a dial-in number and unique PIN prior to the call.

What will Myriad management cover during the Q3 2025 earnings call for MYGN?

Management will provide a financial overview and a business update summarizing company performance for third quarter 2025.

Where will the archived Myriad Genetics (MYGN) Q3 2025 earnings call be posted?

The archived webcast will be available at investor.myriad.com following the conference call.